From the chart, Lovaza U.S. sales totaled approximately $100 million during its first 12 months--very close to analyst projections for Vascepa during its first year.
Lovaza U.S. sales in 2006 and 2007 totaled $138 million and $287 million, respectively, according to a Pronovo annual report from 2007.